Quantitative Characterization of the Effects of Fulvestrant Alone or in Combination with Taselisib (pi3kinase Inhibitor) on Longitudinal Tumor Growth in Patients with Estrogen Receptor-Positive, HER2-negative, PIK3CA-mutant, Advanced or Metastatic Breast Cancer
CANCER CHEMOTHERAPY AND PHARMACOLOGY（2024）
摘要
Among cases of breast cancer, estrogen receptor-positive (ER +), PIK3CA-mutant, HER2- advanced breast cancer stands as a particularly complex clinical indication where approximately 40
更多查看译文
关键词
Breast cancer,Tumor growth inhibition,Combination therapy,Fulvestrant,PI3K inhibitor
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要